Encore Medical, Inc.

FWP supplemental

S-1/A amended

Encore Medical, Inc. filed an S-1/A registration statement amendment, adding exhibits such as the Filing Fee Table and a 2021-2022 Investor’s Warrant. The filing highlights the company's PFO closure device, targeting markets for stroke and migraine treatments, with ongoing FDA trials and commercialization in Europe. The amendment reflects updates to the IPO registration process, including legal and financial disclosures.

FWP supplemental

Encore Medical, Inc. is preparing for its initial public offering (IPO) with a focus on its PFO closure device, targeting the $1.5B+ stroke market and $100B+ migraine market. The filing supersedes a prior Free Writing Prospectus, emphasizing clinical trials, regulatory pathways, and market expansion. Key highlights include a head-to-head FDA-approved trial, CE marking, and $2.5M in 2025 Europe sales. The offering aims to raise $15M (plus over-allotment) for clinical trials, commercial growth, and debt reduction.

FWP supplemental

Encore Medical, Inc. is conducting an initial public offering (IPO) for its PFO closure device, targeting the $1.5B+ stroke market and $100B+ migraine headache market. The company highlights its differentiated technology with superior clinical outcomes, CE marking, and ongoing FDA trials. The offering aims to raise $15 million (plus over-allotment) to fund clinical trials, commercial growth, debt reduction, and working capital. The device has demonstrated high closure rates and minimal metal usage, with 35,000+ implants globally. The IPO follows regulatory progress in Europe and pending U.S. FDA approval.

S-1/A amended

Encore Medical, Inc. is conducting its initial public offering (IPO) of 3,000,000 shares of common stock at an expected price of $5.00 per share, totaling $15 million. The company, which develops transcatheter closure devices for cardiac defects like patent foramen ovale (PFO), highlights its CE Mark approval for international sales and a $1.5 billion potential market for PFO-related stroke prevention. The offering includes underwriter warrants and a 45-day option for additional shares. The IPO is contingent on NYSE American listing and emphasizes risks related to market dependence, regulatory approvals, and competitive pressures.

S-1/A amended

Encore Medical, Inc. files Amendment No. 2 to its Form S-1 to conduct an initial public offering of 3,000,000 shares of common stock. The company expects an IPO price of $5.00 per share (subject to completion of pricing), with net proceeds (before expenses) of $13.8 million at the midpoint shown. The offering is contingent on the company’s common stock being listed on the NYSE American under symbol “EMI.” The prospectus reiterates that the company has no prior public market, identifies the company as an emerging growth company and a smaller reporting company, and describes the underwriting terms including an 8% underwriting discount/fee plus underwriters’ warrants equal to 8% of shares sold, exercisable one year after effectiveness at 120% of the offering price, and a 45-day over-allotment option for up to 450,000 additional shares.

S-1/A amended

Encore Medical, Inc. is conducting an initial public offering (IPO) of 3,000,000 shares of common stock at $5.00 per share, aiming to raise $15 million. The company, an emerging growth company and smaller reporting company, focuses on transcatheter closure devices for structural heart defects, primarily patent foramen ovale (PFO) and atrial septal defects (ASD). The IPO follows CE Mark approval for European sales and clinical trials for FDA clearance in the U.S. The stock is expected to list on NYSE American under the symbol 'EMI,' contingent on regulatory approvals and market conditions.

S-1 filed

Encore Medical, Inc. is conducting its initial public offering (IPO) to register shares of common stock for trading on the NYSE American under the symbol 'EMI.' The company develops transcatheter closure devices for structural heart defects, primarily patent foramen ovale (PFO) and atrial septal defects (ASD). While currently approved for sale in the European Union via CE Mark, the company seeks FDA approval in the U.S. to expand its market. The IPO aims to raise capital for commercialization, clinical trials, and operational growth. As an emerging growth company, Encore benefits from reduced reporting requirements but faces risks related to regulatory approvals, clinical trial outcomes, and market competition.